Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01031498 · ClinicalTrials.gov registry record · Phase 2
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT01031498: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01031498 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01031498, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to compare the effectiveness of 3 drug schedules in preventing chemotherapy-related nausea and/or vomiting in patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
Interventions
- DRUG Ondansetron
- DRUG Palonosetron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01031498
The ClinicalTrials.gov registry entry for NCT01031498 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ondansetron is the first listed.
NCT01031498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01031498 about?
NCT01031498 is a clinical study titled "Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting". The goal of this clinical research study is to compare the effectiveness of 3 drug schedules in preventing chemotherapy-related nausea and/or vomiting in patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
What is the current status of trial NCT01031498?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2005-09. Estimated completion is 2009-09.
What interventions are being tested in trial NCT01031498?
The interventions under investigation include: Ondansetron (DRUG), Palonosetron (DRUG).
Who is sponsoring clinical trial NCT01031498?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.